>_ QFI Terminal
TerminalStocks › FLNA

Filana Therapeutics, Inc. (FLNA) Stock

Healthcare · Biotechnology · US
$0.73 +0.83%
Last updated Sep 20, 2026 14:57 UTC

FLNA Key Statistics

Market Cap$35.07M
P/E (TTM)-0.83
P/S (TTM)
P/B (TTM)0.55
Revenue (TTM)$0.00
EPS (TTM)$-0.87
Dividend Yield
ROE (TTM)-58.78%
Net Margin0.00%
Gross Margin0.00%
52W High$2.49
52W Low$0.67
Analyst View
Price Target
Employees19
Volume122,726

About Filana Therapeutics, Inc.

Filana Therapeutics, Inc. is a company dedicated to pioneering new pharmaceutical products and diagnostic technologies. A key area of its research is focused on creating potential treatments for Alzheimer's disease, including the investigational compounds PTI-125 and PTI-125Dx. Established by Remi Barbier in May 1998, the firm maintains its principal office in Austin, Texas.

CEO: Richard Jon Barry. Company website

FLNA — Frequently Asked Questions

What is the FLNA stock price today?

Filana Therapeutics, Inc. (FLNA) trades at $0.73, up 0.83% on the day, as of Sep 20, 2026 14:57 UTC.

What is Filana Therapeutics, Inc.'s market cap?

Filana Therapeutics, Inc. has a market capitalisation of $35.07M, calculated from the live FLNA share price and shares outstanding.

What is the P/E ratio of FLNA?

FLNA has no meaningful price-to-earnings ratio: Filana Therapeutics, Inc. lost $0.87 per share over the last twelve months, and a P/E is only defined on positive earnings.

How much revenue does Filana Therapeutics, Inc. make?

Filana Therapeutics, Inc. generated revenue of $0.00 over the trailing twelve months.

What is the 52-week range for FLNA?

FLNA has traded between $0.67 and $2.49 over the past 52 weeks, and the last price is 70.8% below that high.

Is Filana Therapeutics, Inc. profitable?

Yes. Filana Therapeutics, Inc. keeps 0.00% of revenue as net income over the trailing twelve months.

What sector is Filana Therapeutics, Inc. in?

Filana Therapeutics, Inc. is classified under the Healthcare sector and the Biotechnology industry, and is domiciled in US.

Who is the CEO of Filana Therapeutics, Inc.?

Richard Jon Barry is the chief executive of Filana Therapeutics, Inc., which employs 19 people.

Where can I track FLNA in real time?

QFI Terminal shows FLNA with live charts, full financials, the options chain with gamma exposure, institutional ownership and analyst ratings on one screen. The free plan has no time limit and asks for no card.

See FLNA live in QFI Terminal

Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.

Open FLNA in Terminal See plans

Biotechnology stocks

REGN Regeneron Pharmaceuticals, Inc. VRTX Vertex Pharmaceuticals Incorporated ONC BeOne Medicines AG ARGX argenx SE INCY Incyte Corporation ALNY Alnylam Pharmaceuticals, Inc. JAZZ Jazz Pharmaceuticals plc GMAB Genmab A/S

More Healthcare stocks

UNH UnitedHealth Group Incorporated CVS CVS Health Corp. MCK McKesson Corporation COR Cencora, Inc. NVO Novo Nordisk A/S CI Cigna Corporation CAH Cardinal Health, Inc. ELV Elevance Health Inc.